<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
  <journal-id journal-id-type="publisher-id">58</journal-id>
  <journal-id journal-id-type="short-title">gdddr</journal-id>
  <journal-id journal-id-type="doi">10.31703/gdddr</journal-id>
  <journal-title-group>
    <journal-title>Global Drug Design &amp; Development Review</journal-title>
    <abbrev-journal-title abbrev-type="publisher">gdddr</abbrev-journal-title>
  </journal-title-group>
  <issn publication-format="print">2788-497X</issn>
  <issn publication-format="electronic">2788-4120</issn>
  <self-uri xlink:href="https://gdddrjournal.com"/>
  <publisher>
    <publisher-name>Humanity Publications</publisher-name>
    <publisher-loc>Pakistan</publisher-loc>
  </publisher>
</journal-meta>
<article-meta>
  <article-id pub-id-type="publisher-id">393100</article-id>
  <article-id pub-id-type="doi">10.31703/gdddr.2017(II-I).05</article-id>
  <article-id pub-id-type="other" specific-use="submission-id">3569</article-id>
  <article-version article-version-type="publisher">1.0</article-version>
  <article-categories>
    <subj-group subj-group-type="heading">
      <subject>article</subject>
    </subj-group>
  </article-categories>
  <title-group>
    <article-title xml:lang="en">A Literature Study of IPQC (In Process Quality Control) tests and FDF (Finished Dosage Form) tests for Parenteral Dosage forms taking Adicovil IV Ampoule as an Example.</article-title>
  </title-group>
<contrib-group>
  <contrib contrib-type="author" seq="1" corresp="yes">
    <name>
      <surname>Sabir</surname>
      <given-names>Ayesha</given-names>
    </name>
    <email>saqibjalal@gssrjournal.com</email>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
    <xref ref-type="aff" rid="aff1"/>
    <xref ref-type="corresp" rid="cor1"/>
  </contrib>
  <contrib contrib-type="author" seq="2">
    <name>
      <surname>Fatima</surname>
      <given-names>Syeda Komal</given-names>
    </name>
    <email>saqibjalal@gssrjournal.com</email>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff1"/>
  </contrib>
  <contrib contrib-type="author" seq="3">
    <name>
      <surname>Kaleem</surname>
      <given-names>Asma</given-names>
    </name>
    <email>saqibjalal@gssrjournal.com</email>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff1"/>
  </contrib>
  <contrib contrib-type="author" seq="4">
    <name>
      <surname>Altaf</surname>
      <given-names>Sidra</given-names>
    </name>
    <email>saqibjalal@gssrjournal.com</email>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff1"/>
  </contrib>
  <contrib contrib-type="author" seq="5">
    <name>
      <surname>Khan</surname>
      <given-names>Imran</given-names>
    </name>
    <email>saqibjalal@gssrjournal.com</email>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff2"/>
  </contrib>
  <aff id="aff1">
    <label>1</label>
    <institution-wrap>
      <institution>Undergraduate Students, Department of Pharmacy, Quaid I Azam University</institution>
    </institution-wrap>
    <addr-line>Islamabad</addr-line>
    <country>Pakistan</country>
  </aff>
  <aff id="aff2">
    <label>2</label>
    <institution-wrap>
      <institution>Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore</institution>
    </institution-wrap>
    <named-content content-type="author-role">Associate Professor</named-content>
    <addr-line>Punjab</addr-line>
    <country>Pakistan</country>
  </aff>
</contrib-group>
<author-notes>
  <corresp id="cor1">Corresponding Author: Ayesha Sabir, Undergraduate Students, Department of Pharmacy, Quaid I Azam University, Islamabad, Pakistan.. Email: <email>saqibjalal@gssrjournal.com</email></corresp>
<fn fn-type="COI-statement" id="fn-coi">
  <p>The authors declare that they have no conflicts of interest.</p>
</fn>
<fn fn-type="ethics-statement" id="fn-ethics">
  <p>This study did not require formal ethics approval.</p>
</fn>
<fn fn-type="data-availability-statement" id="fn-data">
  <p>Data sharing is not applicable to this article.</p>
</fn>
</author-notes>
<pub-date pub-type="epub" date-type="pub" publication-format="electronic">
  <day>31</day>
  <month>12</month>
  <year>2017</year>
</pub-date>
<pub-date pub-type="collection">
  <month>12</month>
  <year>2017</year>
</pub-date>
<pub-date date-type="pub" publication-format="print">
  <day>03</day>
  <month>10</month>
  <year>2022</year>
</pub-date>
  <volume>2</volume>
  <issue>1</issue>
  <season>Fall</season>
  <fpage>44</fpage>
  <lpage>55</lpage>
  <history>
    <date date-type="accepted">
      <day>03</day>
      <month>10</month>
      <year>2022</year>
    </date>
  </history>
<funding-group>
  <funding-statement>
<p>The authors received no specific funding for this work.</p>
  </funding-statement>
</funding-group>
<permissions>
  <copyright-year>2017</copyright-year>
  <copyright-holder>Humanity Publications</copyright-holder>
  <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License.</license-p>
  </license>
</permissions>
<self-uri content-type="text/html" xlink:href="https://gdddrjournal.com/article/a-literature-study-of-ipqc-in-process-quality-control-tests-and-fdf-finished-dosage-form-tests-for-parenteral-dosage-forms-taking-adicovil-iv-ampoule-as-an-example"/>
<self-uri content-type="pdf" xlink:href="https://gdddrjournal.com/pdf/gdddr/G8XEJ2OTSS.pdf"/>
<supplementary-material id="suppl-pdf" content-type="pdf" xlink:href="https://gdddrjournal.com/pdf/gdddr/G8XEJ2OTSS.pdf">
  <label>PDF</label>
  <caption>
    <title>Full Text PDF</title>
  </caption>
</supplementary-material>
  <abstract>
    <p>This study was conducted to evaluate both the in-process quality control tests as well as the finished dosage form tests for a parenteral product. Furthermore, all the processes from the purchase of API to marketing of product were studied. A batch of Adicovil was taken Adicovil was taken as an example, it is small volume parenteral of 2ml ampoule that is studied to evaluate its efficacy and stability by performing chemical and physical tests. IPQC tests for type I glass includes powder glass test, while for water for injection they are pH, acidity &amp; alkalinity, non-volatile matter, ammonium ions, non-oxidizable matter, sterility and pyrogen test. Test for finished dosage form of Adicovil are identification, leaker test, clarity test, sterility, pyrogen test, BET, deliverable volume and determination of volume of injection for container. The selected batch of Adicovil passed all the IPQC and FDF tests in the procedure.</p>
  </abstract>
<kwd-group kwd-group-type="author-keywords">
  <kwd>Parenteral</kwd>
  <kwd>IPQC</kwd>
  <kwd>stability tests</kwd>
  <kwd>FDF</kwd>
  <kwd>physical tests</kwd>
  <kwd>chemical tests.</kwd>
</kwd-group>
  <custom-meta-group>
    <custom-meta><meta-name>views</meta-name><meta-value>1993</meta-value></custom-meta>
    <custom-meta><meta-name>downloads</meta-name><meta-value>0</meta-value></custom-meta>
    <custom-meta><meta-name>html-views</meta-name><meta-value>0</meta-value></custom-meta>
    <custom-meta><meta-name>google-scholar-citations</meta-name><meta-value>0</meta-value></custom-meta>
    <custom-meta><meta-name>crossref-citations</meta-name><meta-value>0</meta-value></custom-meta>
  </custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec-1">
  <title>Introduction</title>
<p>Parenteral preparations known as the sterile preparations consists of one or more active ingredients intend to administer other than oral route that is by injection, infusion or by implantation into the body. These preparations are packaged in single-dose or multidose containers. The Small-volume Injection is packaged in the containers which are labeled as containing 100 mL or less. Large volume parenteral provide electrolytes, dextrose solution has volume 101-1000ml. (Akers, Larrimore, &amp; Guazzo, 2002)</p><p>Parenteral dosage forms must be stable, sterile, free from the pyrogens and toxins. They should also isotonic and chemically pure.</p><p>Different tests are performed for their evaluation like sterility test, leakage test, pyrogen test clarity test and assay are also performed to evaluate these preparations. (Awan, Raouf, Ahmad, Sparks, &amp; Marketing, 2009)</p><p><break/></p><p>Description</p><p>The product chosen is a 2ml ampoule of Adicovil, generic name is Pheniramine maleate, brand name is Adicovil, manufactured by Ameer and Adnan Pharmaceutical Pvt Ltd. for IV administration only.</p><p>The formats given below is acceptable for the contents which is of greater than 1 mL: API (Pheniramine Maleate) -------50mg</p><p>Water for injection----------q.s</p><p>Strength and total volume format as per USP</p><p>(total------2ml) strength/volume: 50 mg/2 mL Strength/mL: 25 mg/mL</p><p><break/></p><p>Purchase of API</p><p>API of Pheniramine maleate was purchased from Biesterfield Pharma at price of 1.5 lakh PKR per kg. It was packaged in a fiber HDPE drum with double plastic bags inside and a capacity of 25kg and a shelf life of 5 years, provided that it should be kept in a clean, dry, cool area that is away from direct sunlight and the moisture.</p><p><break/></p><p>Physical properties of API</p><p>White colored powder, 134-135 C melting point,</p><p><break/></p><p>Role of QA and QC inspector in industry</p><p>Role of QA Inspector</p><p>•	First rule is to make and approve the Quality Policy, its Objectives, Manual and Validation Master Plan.</p><p>•	Second is making of periodic planning of objectives of quality.</p><p>•	All validation &amp; stability activities are monitored and then completed according to the schedule.</p><p>•	It is also made sure that all changes have impact on the product and the established systems are being regularly documented and reviewed.</p><p>•	It is necessary to ensures that all market complaints are registered, investigated to find out the basic cause so as to take CAPA to stop recurrence.</p><p>•	It is necessary to prepare Annual product quality reports, trending of the data, analyzing product and performance of process.</p><p>•	Last step is to arrange and conduct the self-inspection, find out the gaps and  then take CAPA, records of related batch manufacturing are reviewed and QC testing data  is performed before to release of  batch.</p><p><break/></p><p>Line Clearance</p><p>Line clearance has importance in pharmaceutical manufacturing. It makes sure   that the processes are according to the set the standard operating procedure. For the line clearance in preparation area quality assurance is required. It has following steps.</p><p>1.	Dispensing</p><p>2.	Separate clearance necessary for all those processes happening in manufacturing.</p><p>3.	Filling</p><p>4.	Batch production and packaging</p><p><break/></p><p>Role of QC Inspector</p><p>•	Routine work: He is responsible for daily RM &amp; PM inspection, Intermediate stage inspection, Finished Products analysis and the Stability analysis.</p><p>•	Non-Routine:  Calibration &amp; maintenance of instruments, Preparation of reference/ working standards and the Method of development are also performed by inspector.</p><p>•	Activities managed through: Analysis of instruments, inspection of chemicals (RM &amp; FG), Analysis of microbiological product and the inspection of packaging materials.</p><p>•	Performing out Sampling and testing of products, Monitoring of environmental conditions, Conduction of stability studies, Investigation of test failures such as OOS / OOT / OOAC / OOAL, validation of Analytical method and then Evaluation of the complaint samples. (Banker, 1970)</p><p><break/></p><p>Operational procedures</p><p>Physical facilities</p><p>Brick buildings, well lighted and air-conditioned areas, automated fire alarm, a raw material quarantine area.</p><p>Locked vaults for controlled substances. Separate rooms for different dosage forms. (Broadhead, Gibson, &amp; Form, 2009)</p><p><break/></p><p>QC Facilities</p><p>A bench, desk, hood must be provided to scientist or technician.</p><p><break/></p><p>Receipt of Raw Material</p><p>When a raw material is received, it is assigned a receiving number, indicated on containers and in QC records and is tagged with a “Quarantine” label. It indicates product’s identity, source, grade, quantity, and data received.</p>
</sec>
<sec id="sec-2">
  <title>QC of Raw Material</title>
<p>A representative of each raw material received is withdrawn for analysis by the Raw Material Control department, the remaining is impounded in raw material quarantine area. Passed labelled items are accepted, while ones not meeting the requirement are labelled Rejected.</p><p><break/></p><p>Master Formula File</p><p>A complete file for each product is maintained by quality control, containing master formula record, current label, and labeling copy, details about packaging, etc.</p><p><break/></p><p>Master Formula Record</p><p>Prepared by technical committee with members from R&amp;D, QC and manufacturing.</p><p><break/></p><p>Batch Production Card</p><p>Initiated by director of QA. Lot number is assigned, and calculations of ingredients are made.</p><p><break/></p><p>Issuance of Raw Material</p><p>Raw material department receives notification of lot number and product and prepares raw material requisition cards for rich ingredient.</p><p><break/></p><p>Identification of Manufacturing Steps and Machines</p><p>Each is identified with a label, showing its name, lot number, batch size.</p><p>Sampling</p><p>Testing</p><p>Packaging</p><p><break/></p><p>Different Portions of Industry</p><p>Area Planning and Environmental Control</p><p>Area planning is addressed to the basic functional groups ground. It is very critical area in which special attention is given to maintain the cleanliness.</p><p><break/></p><p>Functional Groupings</p><p>Warehousing</p><p>•	To store the spare parts, change parts, air filters, chemicals used in water treatment, office supplier, uniforms and so many might be handled by central storage or individual storage by that department.</p><p>•	Finished product and other essential raw chemicals require particular environmental conditions for storage like temperature control and the humidity control.</p><p>Administrative Areas</p><p>•	Administrative area planning needs particular analysis of direct and indirect requirements of specific plants.</p><p><break/></p><p>Environmental Control Zone Grouping</p><p>Zones</p><p>•	White zone: it is last step (parenteral products are filled here)</p><p>•	Grey zone: it includes weighing, filtration and dissolution.</p><p>•	Black zone: it contains storage. It is the worst area according to contamination point.</p>
</sec>
<sec id="sec-3">
  <title>Figure 1</title>
<p>Black, white &amp; gray area</p>
</sec>
<sec id="sec-4">
  <title>Zone 1</title>
<p>It consists of the maintenance of sterile areas.</p><p><break/></p><p>Zone 2 plant exterior</p><p>It is the basic zone from which to we determine the requirements to do work for the various control barriers.</p><p><break/></p><p>Zone 3 General Production and Administration Area</p><p>it is the third zone for environmental controls  and it is made by the periphery of the general manufacturing area.</p><p><break/></p><p>Zone 4 Clean Area</p><p>In this zone activities cleaning, washing  and  preparations of instruments or accumulation and  finally  sampling of the finished products is performed.</p><p><break/></p><p>Zone 5 Weighing, Mixing, and Transfer Area</p><p>This Zone 5 ensures the activities of “balancing,  mixing, filling ,weighing “ addressed by c GMP section 212.81 that are not handled in zone  6 but they need a controlled environment.</p><p><break/></p><p>Zone 6 Filling Area</p><p>it is very distinct zone for  the controlled  environment area where an aseptic filling function is carried out. It is not specific zone for non-aseptic filling function. (Ennis et al., 2001)</p><p><break/></p><p>Wall &amp; Floor Treatment</p><p>Requirements for cleanliness includes plain, cleanable walls, ceilings, fixtures, and separated exposed walls, studs, columns ,pipes and bracings are not acceptable. The requirement  for cleanliness also removes the open floor system that is used for laminar air flow system.</p><p><break/></p><p>Lightning Fixtures</p><p><break/></p><p>Lighting fixtures must be less redden with  the ceiling. Areas which have a full HEPA  ceiling could not lodge dented lighting  fixtures. These areas have special fixtures which  are of a  “tear drop” forms that reduces disturbance to the laminar airflow pattern.</p><p><break/></p><p>Change Rooms</p><p>Personnel approach to all the  controlled areas must be via changing rooms. These  Changing rooms give ideas and setups that vary from a  single size room to  high-priced multi-room complexes. Vestibules are used as entry gate to enter the changing area, its doors are interlocked electrically such that  both doors are not opened at the same time, by  maintaining the air pressure differential so that  airborne contamination must be blocked. Wash skins  are given to scrub hands and forearms after gaining entry into room. Filtered and heated compressed air is used further for drying purpose. When hands become dried, clothes  taken  from the  dispensers and put on while moving across a  dressing bench. In final  step, aseptic gloves are worn . Exit is just like the entrance. (Haleem, Salem, Fatahallah, &amp; Abdelfattah, 2015)</p><p><break/></p><p>Personnel Flow</p><p>While making the design of individual plant areas motion of individuals must be planned. Each personal manufacturing are must  have a plain  and efficient flow pattern,  it could develop a congested pattern. It is an inefficient way if flow of chemicals made through corridors and unsafe when different individual manufacturing area plants are combined.</p>
</sec>
<sec id="sec-5">
  <title>Figure 2</title>
<p>Correct design (left), incorrect design (right)</p><p>Utilities and Utility Equipment Location</p><p>Utilities</p><p>It is important to clean Piping system in particular initially and periodically. When it comes to exposed overhead then this kind of piping is not allowable from a cleanliness or contamination point because it gathers dust, so it is hard to clean and it might leak. Buried or enfold pipe might need unallowable destruction for cleaning or recovery. (Janodia &amp; Udupa, 2015)</p><p><break/></p><p>Utilities Equipment Location</p><p>Public services need space for dealing. Additionally, for switching devices and transformer electrical power system is needed. (Modgil &amp; Sharma, 2016)</p><p>To make sure consistent quality treatment of water system is required. Plant generated services need steam boilers, pneumatic compressors, and distillation and the “boiler room” application. In foul weather, especially winter, maintenance of instruments is very hard. (Potdar, 2006)</p><p>Heavy instruments might cause harm to the roof-structure, especially when the instrument location needs much penetrations via the roof that is equipped with instrument vibration, will invariably lead to leakage.</p><p><break/></p><p>Engineering and Maintenance</p><p>In view of engineering stand-point, any location if even it is exterior to the plant may serve good but approach to the manufacturing area by architects for field work must not too hard especially in small or less complex plants. (Schaut, Weeks, &amp; technology, 2017)</p><p>Maintenance responsibilities include whole areas  of the plant and may be divided into two  forms: plant maintenance and production  maintenance.</p><p><break/></p><p>List of Equipment</p><p>Manufacturing Area</p><p>1.	Storage instruments required for vials ,ampules ,bottles and  closures</p><p>2.	parching and washing instrument</p><p>3.	 Cabinet that is dirt proof</p><p>4.	Blending  and manufacturing tanks</p><p>5.	Blending instruments  where needed</p><p>6.	Filtering instrument</p><p>7.	Hot air cleaner</p><p><break/></p><p>b) Aseptic filling and sealing room</p><p>8.	Counters for lining and sealing</p><p>9.	 Filters for Bacteriological</p><p><break/></p><p>C) General room</p><p>10. Examination table</p><p>11. Exude testing table</p><p>12.	Benches for Labeling and packaging</p><p>13. For instruments storage consists of cold and refrigerators stockpile if needed</p>
</sec>
<sec id="sec-6">
  <title>Figure 3</title>
<p>A Summary of Industrial Processing</p><p>Processing of type, I glass Ampoules</p><p>Purchase of Glass</p><p>The industry purchased glass from Ganj Glass Works Ltd. 12mm tempering glass was purchased at a price of PKR 800/sift with a bulk order of 5000 sift. The company has a production capacity of 200 tons glass per day.</p><p><break/></p><p>Why use type I glass?</p><p>The  best opposition to thermal shock  is provided by type 1 borosilicate glass and it is higher chemical resistance. This type of glass shows the slightest reactive glass. It gives higher longevity, heat and the chemical  resistance. It consists of notable quantity of aluminum oxide ,boric oxide and alkali and alkaline earth oxides.</p><p><break/></p><p>Manufacturing Ampoules</p><p>Fabrication</p><p>In industry ampoules are formed  from small lengths of glass tubing,  that are made by warming  with gas lamping and  by the gravity in  an automatic manufacturing  lines. For the control of quality  Computer vision techniques are used.</p><p><break/></p><p>Ampoule code</p><p>Ampoules are basically in red color and are ringed along the neck so it becomes easy to find out the ingredient inside it. The rings which are machine-legible and permit for correct handling of the ingredient for the objective of labelling, storage, and secondary packaging.</p><p><break/></p><p>Opening</p><p>they are unfastened by chalking up the neck and breaking the top off. In the &quot;one-point cut&quot; (OPC ampoules) a point overhead the neck finds out the place of a small slit in the glass for opening of the ampoule.</p><p><break/></p><p>Filling and sealing</p><p>The filling and sealing of ampoules is done by the use of JLAB Ampoule Filling Machine with a production capacity of 1000.  Before and after filling of liquid into ampoules nitrogen is purged in, so to eliminate atmospheric air present in it. Hermetic sealing is performed by a burner which is present in that device, it liquefies the things top and then break the neck. Overhead the device empty space left is filled with nitrogen. (Shirisha, Ghosh, Rajni, Banji, &amp; Technology, 2014)</p><p><break/></p><p>Labelling ampoules</p><p>Name of machine: ALPHARMA A</p><p>Specifications</p><p>150 products/min is the speed, power supply of 400 V, 50 Hz three-phase, power consumption of 1kW.</p><p><break/></p><p>Labelling (USP 32 &lt;1&gt;)</p><p>The label on the container or device shows the name of the product, its drug percentage content of drug in a specific volume, conditions for storage and an expiry date, the location and name of business of the manufacturer, and lot number. The lot number is able to yield the full preparation history of the specified package, containing whole preparation, sterilizing, filling and labeling operations.</p><p><break/></p><p>Table 1: Square Meter of Area Required in an Industry</p>
</sec>
<sec id="sec-7">
  <title>Qualitative Layout of Parenteral Manufacturing</title>
<p><bold>Processing Of Water
For Injection</bold></p><p>USP 32 &lt;1&gt; shows that water for the injection has
always been utilized as solvent unless specified in the individual monograph.
There is no preservative   less than
the   5 ml.</p><p><bold>Production</bold></p><p><bold>Single Effect
Distillation</bold></p><p>Ø  BRAM-COR <bold>Single Effect
Distiller</bold> Mod. <bold>DPSG</bold> is a Still along with
a Pure Steam Generator. The manufacturing method contains evaporation of PW
water by   separation of pure steam and
then condensation. By utilizing centrifugal and gravity processes this steam is
refined. This instrument gives dried and
saturated steam that is in in future utilized for sterilizing agent.</p><p>Ø  pure
steam fulfils the all conditions  of international pharmacopoeias for Water for
Injection. The system can therefore provide a simultaneous production of Pure
Steam and Water for Injection by condensing it through the double sheet
condenser.</p><p>Both BRAM-COR <bold>CPSG and  </bold>Pure Steam
Generator yields   dry and saturated
steam: this steam, by condensing ,fulfills 
USP conditions for <bold>Water for
Injection</bold>(WFI).</p><p><bold>Storage</bold></p><p>The freshly prepared water is when stored and then sterilized
in containers or devices that are hermitically sealed, it will be in very good
condition. (Williams, 2004)</p><table-wrap id="table1"><label>Table 2</label><caption><title>Specifications of Water For Injection</title></caption><table><tbody><tr><td> <p><bold>S. No</bold></p> </td><td> <p><bold>Parameters</bold></p> </td><td> <p><bold>Specifications</bold></p> </td></tr><tr><td> <p>1</p> </td><td> <p>Appearance</p> </td><td> <p>clear, colorless, no visible particles</p> </td></tr><tr><td> <p>2</p> </td><td> <p>Odor</p> </td><td> <p>Odorless</p> </td></tr><tr><td> <p>3</p> </td><td> <p>pH</p> </td><td> <p>5.0-7.0</p> </td></tr><tr><td> <p>4</p> </td><td> <p>Acidity or alkalinity</p> </td><td> <p>NMT 0.1 ml of 0.01M NaOH/Hcl</p> </td></tr><tr><td> <p>5</p> </td><td> <p>Chloride</p> </td><td> <p>0 ppm</p> </td></tr><tr><td> <p>6</p> </td><td> <p>Oxidizable Substances</p> </td><td> <p>0 ppm</p> </td></tr><tr><td> <p>7</p> </td><td> <p>Sulphate</p> </td><td> <p>0 ppm</p> </td></tr><tr><td> <p>8</p> </td><td> <p>Total hardness</p> </td><td> <p>0 ppm</p> </td></tr><tr><td> <p>9</p> </td><td> <p>Total dissolved solid (TDS)</p> </td><td> <p>NMT 10 ppm</p> </td></tr><tr><td> <p>10</p> </td><td> <p>Conductivity</p> </td><td> <p>NMT 0.1 ms</p> </td></tr><tr><td> <p>11</p> </td><td> <p>Microbial count</p> </td><td> <p>10 cru/100 ml</p> </td></tr></tbody></table></table-wrap><p><bold>Water
Supply to Industry</bold></p><p>“(GMP)
Water Distribution Pipe 14.40. The distribution of PW, HPW and WFI should be
accomplished using a continuously circulating pipework loop. Proliferation of
contaminants within the storage tank and distribution loop should be
controlled. Filtration should not usually be used in distribution loops or at
take-off user points to control bio-contamination. Such filters are likely to
conceal system contamination.”</p><p>Water
from the Karachi sea is used by this industry. To get this water connection,
attested photocopy of CNIC of owner, attested photocopy of sale proof/deed of
ownership, copy of assessment, specification of departments using water, site
plan to indicate location of property are to be provided to office of Sub
Divisional Officer WASA in Karachi, and it is to specified that the connection
is metered industrial one. A connection agreement is signed. An estimated bill
for 6 months us included in the challan submitted which is later adjusted in
monthly bills.</p><p><bold>In
Process Quality Control Tests</bold></p><p><bold>IPQC Test For Type I
Glass</bold></p><table-wrap id="table2"><label>Table 3</label><caption><title>Powdered Glass Test</title></caption><table><tbody><tr><td colspan="5" valign="top"> <p><bold>Glass Type and Test Limit</bold></p> </td></tr><tr><td valign="top"> <p><bold>Type</bold></p> </td><td valign="top"> <p><bold>General Description</bold></p> </td><td valign="top"> <p><bold>Type of test applied</bold></p> </td><td colspan="2" valign="top"> <p><bold>Limits</bold></p> </td></tr><tr><td valign="top">  </td><td valign="top">  </td><td valign="top">  </td><td valign="top"> <p>Size sq, ml</p> </td><td valign="top"> <p>ml of cb 0.02N acid</p> </td></tr><tr><td valign="top"> <p>I</p> </td><td valign="top"> <p>Highly resistant, borosilicate glass</p> </td><td valign="top"> <p>Powdered glass test</p> </td><td valign="top"> <p>All</p> </td><td valign="top"> <p>1.0</p> </td></tr></tbody></table></table-wrap><p><bold>Tests
for water for Injection</bold></p><p>1)       
<bold>pH</bold><bold>:</bold> Between 5-7, determined
potentiometrically.</p><p>2)       
<bold>Acidity or Alkalinity</bold><bold>:</bold> 1 drop of phenol red solution is added
into 20ml of it. When it is of yellow, it changes into red on addition of 0.1ml
of 0.01N NaOH; while when solution is red, it turns into yellow by addition of
0.1ml of 0.01N HCl.</p><p>3)       
<bold>Copper, Iron and lead</bold><bold>:</bold> 1 drop of sodium sulfide solution is
added to 100ml of it, then liquid keeps plain and clear.</p><p>4)       
<bold>Chloride</bold><bold>:</bold>  
1ml of Barium chloride solution is added to 100ml of it then after it
make it almost to stand for five to six minutes; the liquid resets as clear and
colorless.</p><p>5)       
<bold>Ammonia</bold><bold>:</bold> 2ml of alkaline potassium mercuric
iodide solution is added to 50ml of it then see   in a Nessler cylinder that is ranking  on the white side; yellow color generated
quickly  is not darker as compared to
that formed by 50ml of ammonia-free water by adding dilute ammonium chloride
solution.</p><p>6)       
<bold>Calcium</bold><bold>:</bold> 
2ml of ammonium oxalate solution is added to 100ml of it, there is no
turbidity.</p><p>7)       
<bold>Carbon Dioxide</bold><bold>:</bold> 
25ml of calcium hydroxide solutions is added to 25 ml of it; the mixture
remains clear.</p><p>8)       
<bold>Oxidizable matter</bold><bold>:</bold> first Boil 100ml of it for almost
three minutes with dilute sulphuric acid of 10ml; then   add 0.1ml of 0.1N potassium permanganate and
again boil it for 10 minutes, then pink color of it cannot completely
disappear.</p><p>9)       
<bold>Total solids</bold><bold>:</bold> first of all, 100ml is evaporated on a
water bacth until it goes to dryness and dry the residue at about 105 degree
for almost 1 hour, that is not more than 1 mg of residue remains. (10ppm)</p><p>10)     
<bold>Non-volatile matter</bold><bold>:</bold> First of all, vaporize 100ml until to
dryness on water bath, at 105 degrees for almost one hour dried the residues,
that must not more than 2mg of residue remains (20ppm). In glass container  WFI is packaged and then  sterilized with a size of 30ml or less, the
total solids  content must not be
over  40 ppm, and when in containers of
more than 30ml but not more than 100ml volume, the total solids content must
not excel 30ppm.</p><p>11)     
<bold>Sterility</bold><bold>:</bold> it must fulfill the criteria for
sterility.</p><p>12)     
<bold>Pyrogen</bold><bold>:</bold> it must comply with the test for
pyrogens.</p><p><bold>Test
for API</bold></p><p><bold>Assay:</bold> assay is carried out with Injection, to make the solution
used to determine the absorbance, <italic>A<sub>U</sub></italic>, at the 264
nm wavelength. To determine <italic>A<sub>S</sub></italic>, we add about 25 mg of Adicovil, weighed correctly, in 20 mL of dilute sulfuric acid
(1 in 350), and   this solution is
treated the same just like   the portion
of Injection is being assayed.  At the
end quantity is calculated in mg, of C<sub>16</sub>H<sub>19</sub>ClN<sub>2</sub>·C<sub>4</sub>H<sub>4</sub>O<sub>4</sub> in each mL of the Injection by using the formula:</p><p>(<italic>C</italic> / <italic>V</italic>)(<italic>A<sub>U</sub></italic> / <italic>A<sub>S</sub></italic>)</p><p><bold>Finished
Dosage Form Tests</bold></p><p><bold>Identification: (USP 32)</bold></p><p>A:
first volume of Injection is diluted equivalent to get about 50 mg of
chlorpheniramine maleate, with   dilute
hydrochloric acid (1 in 1000) to 25 mL, and then we forwarded it as given specification.</p><p>B: a
volume of Injection is vaporized on steam bath until to dried   that is equivalent to about 25 mg of
chlorpheniramine maleate, and then residue is dried  at 105 for 1 hour: it liquefies between 128
and 135.</p><p><bold>Leaker Test</bold></p><p>It is utilized to identify incomplete
closed containers or devices so they could be released. More chances are for
tip sealed ampules to be closed incompletely as compared to pull-sealed
ampoules. Leakers are identified by giving negative pressure inside in
completed closed ampoules, mostly in a vacuum chamber, by immersing ampules in
a deep colored dye solution (1% methylene blue).</p><p><bold>Clarity test</bold></p><p>Clarity is evaluated by individual human inspection of each
container under good, and light bounces back to eyes, and is seen opposite to
black and white background, by setting the contents in with a movement. A: The
solid disperses fully, leaving behind no visible matter which is not dissolved.</p><p>B: The formed solution is not notably
less plain and colorless as compared to an equivalent volume of the refined
water that present in a similar bottle and examined as it is</p><p><bold>Sterility test</bold></p><p>For a batch containing 400 ampoules
manufactured, 10 containers were used and half of the content of each container
was tested. Method used was membrane filtration. This product meets the
requirements for the test of sterility.</p><p><bold>Pyrogen test</bold></p><p>it is used to control
to an allowable level the chances of burning reaction   by injection in the patient, of the product
that is concerned. This product fulfills the requirements for absence of
pyrogens, none of the rabbits tested showed a rise of more than 0.5 degree.</p><p><bold>BET</bold></p><p>It contains not more
than 8.8 USP Endotoxin Units per mg of chlorpheniramine
maleate.</p><p><bold>pH</bold></p><p>between 4 to 5.2</p><p><bold>Limits for the Particulate
Matter Test:</bold></p><table-wrap id="table3"><label>Table 4</label><caption><title>Limits for Particulate Matter Test</title></caption><table><tbody><tr><td> <p><bold>Method</bold></p> </td><td> <p><bold>Limits</bold></p> </td></tr><tr><td> <p>Light
  blockage</p> <p>HIAC
  counter</p> </td><td> <p>? 10 um: max. 10,000/container</p> <p>? 25 um: max. 1000/container</p> </td></tr></tbody></table></table-wrap><p><italic>Essentially free from visible particles.</italic></p><p><bold>Deliverable volume</bold></p><p>Ten ampoules were taken from this
batch, the AV10 for ten containers was less than 100% and none of the chosen
containers had a volume less than 95% of the average volume, so batch was
accepted.</p><p><bold>Determination of volume of injection
for containers</bold></p><p>In case containers inspectedindividually
the volume must not be less than the nominal
volume,while  in the case of containers
which have their  a nominal volume which
is of 2 mL or less, it must not  less
than the total  of the nominal volumes of
the containers draw together.</p>
</sec>
<sec id="sec-8">
  <title>Conclusion</title>
<p>After performing certain IPQC and finished dosage forms test on 10 containers of Adicovil this batch was accepted as no container had volume less than 95 percent and the average volume was less than 100 percent. One container did not meet the all requirements but overall Batch of Adicovil fulfils the criteria of sterility, pyrogen and clarity test. So, it was accepted to release in market. Bacterial endotoxin content was not more than 8.8 USP endotoxin units per mg chlorpheniramine maleate.</p>
</sec>
</body>
<back>
<fn-group content-type="conflict-of-interest">
  <title>Conflict of Interest</title>
  <fn fn-type="conflict">
<p>The authors declare that they have no conflicts of interest.</p>
  </fn>
</fn-group>
<fn-group content-type="ethics-statement">
  <title>Ethics Statement</title>
  <fn fn-type="ethics">
<p>This study did not require formal ethics approval.</p>
  </fn>
</fn-group>
<fn-group content-type="data-availability">
  <title>Data Availability</title>
  <fn fn-type="data-availability-statement">
<p>Data sharing is not applicable to this article.</p>
  </fn>
</fn-group>
<app-group>
  <app id="app-suppl">
    <title>Supplementary Materials</title>
<supplementary-material id="suppl-pdf" content-type="pdf" xlink:href="https://gdddrjournal.com/pdf/gdddr/G8XEJ2OTSS.pdf">
  <label>PDF</label>
  <caption>
    <title>Full Text PDF</title>
  </caption>
</supplementary-material>
  </app>
</app-group>
<ref-list>
  <title>References</title>
<ref id="Akers">
  <label>1</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Akers, M. K., Larrimore, M. K., &amp; Guazzo, D</person-group>
    <year>2002</year>
    <source>Parenteral quality control: sterility, pyrogen, particulate, and package integrity testing: CRC Press</source>
    <page-range>arenteral</page-range>
    Akers, M. K., Larrimore, M. K., &amp; Guazzo, D. (2002). Parenteral quality control: sterility, pyrogen, particulate, and package integrity testing: CRC Press.
  </mixed-citation>
</ref>
<ref id="Awan">
  <label>2</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Awan, M. U., Raouf, A., Ahmad, N., Sparks, L. J. I. J. o. P., &amp; Marketing, H</person-group>
    <year>2009</year>
    <source>Total quality management in developing countries: A case of pharmaceutical wholesale distribution in Pakistan</source>
    <page-range>harmaceutical</page-range>
    Awan, M. U., Raouf, A., Ahmad, N., Sparks, L. J. I. J. o. P., &amp; Marketing, H. (2009). Total quality management in developing countries: A case of pharmaceutical wholesale distribution in Pakistan.
  </mixed-citation>
</ref>
<ref id="Banker">
  <label>3</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Banker, G. S. J. J. o. P. S</person-group>
    <year>1970</year>
    <article-title>. The theory and practice of industrial pharmacy</article-title>
    <source>59 (10), 1531</source>
    <volume>59</volume>
    <issue>10</issue>
    <fpage>1531</fpage>
    Banker, G. S. J. J. o. P. S. (1970). The theory and practice of industrial pharmacy. 59 (10), 1531.
  </mixed-citation>
</ref>
<ref id="British">
  <label>4</label>
  <mixed-citation publication-type="journal">
    <year>2013</year>
    <source>British Pharmacopeia</source>
    <page-range>harmacopeia</page-range>
    British Pharmacopeia 2013
  </mixed-citation>
</ref>
<ref id="Broadhead">
  <label>5</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Broadhead, J., Gibson, M. J. P. P., &amp; Form, F. A. P. G. f. C. D. S. t. C. D</person-group>
    <year>2009</year>
    <article-title>. Parenteral dosage forms</article-title>
    <source>331- 354</source>
    <page-range>P</page-range>
    Broadhead, J., Gibson, M. J. P. P., &amp; Form, F. A. P. G. f. C. D. S. t. C. D. (2009). Parenteral dosage forms. 331- 354.
  </mixed-citation>
</ref>
<ref id="Ennis">
  <label>6</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Ennis, R. D., Pritchard, R., Nakamura, C., Coulon, M., Yang, T., Visor, G. C., . . . technology</person-group>
    <year>2001</year>
    <article-title>. Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination</article-title>
    <source>6(3), 393-405</source>
    <volume>6</volume>
    <issue>3</issue>
    <fpage>393</fpage>
    <lpage>405</lpage>
    Ennis, R. D., Pritchard, R., Nakamura, C., Coulon, M., Yang, T., Visor, G. C., . . . technology. (2001). Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination. 6(3), 393-405.
  </mixed-citation>
</ref>
<ref id="Haleem">
  <label>7</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Haleem, R. M., Salem, M. Y., Fatahallah, F. A., &amp; Abdelfattah, L. E. J. S. P. J</person-group>
    <year>2015</year>
    <article-title>. Quality in the pharmaceutical industry-A literature review</article-title>
    <source>23(5), 463-469</source>
    <volume>23</volume>
    <issue>5</issue>
    <fpage>463</fpage>
    <lpage>469</lpage>
    Haleem, R. M., Salem, M. Y., Fatahallah, F. A., &amp; Abdelfattah, L. E. J. S. P. J. (2015). Quality in the pharmaceutical industry-A literature review. 23(5), 463-469.
  </mixed-citation>
</ref>
<ref id="Janodia">
  <label>8</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Janodia, M. D., &amp; Udupa, N. J. T. P. R</person-group>
    <year>2015</year>
    <article-title>. Pharmaceutical Packaging-An Overview</article-title>
    <source>89-90</source>
    <page-range>R</page-range>
    Janodia, M. D., &amp; Udupa, N. J. T. P. R. (2015). Pharmaceutical Packaging-An Overview. 89-90.
  </mixed-citation>
</ref>
<ref id="Modgil">
  <label>9</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Modgil, S., &amp; Sharma, S. J. J. o. Q. i. M. E</person-group>
    <year>2016</year>
    <source>Total productive maintenance, total quality management and operational performance: An empirical study of Indian pharmaceutical industry</source>
    <page-range>roductive</page-range>
    Modgil, S., &amp; Sharma, S. J. J. o. Q. i. M. E. (2016). Total productive maintenance, total quality management and operational performance: An empirical study of Indian pharmaceutical industry.
  </mixed-citation>
</ref>
<ref id="Pharmaceutical">
  <label>10</label>
  <mixed-citation publication-type="journal">
    <article-title>Pharmaceutical quality assurance in class, industry and market by Karamat A</article-title>
    <source>Javid</source>
    <page-range>harmaceutical</page-range>
    Pharmaceutical quality assurance in class, industry and market by Karamat A. Javid.
  </mixed-citation>
</ref>
<ref id="Potdar">
  <label>11</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Potdar, M. M. A</person-group>
    <year>2006</year>
    <article-title>. Pharmaceutical quality assurance: Pragati Books Pvt</article-title>
    <source>Ltd</source>
    <page-range>otdar</page-range>
    Potdar, M. M. A. (2006). Pharmaceutical quality assurance: Pragati Books Pvt. Ltd.
  </mixed-citation>
</ref>
<ref id="Schaut">
  <label>12</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Schaut, R. A., Weeks, W. P. J. P. j. o. p. s., &amp; technology</person-group>
    <year>2017</year>
    <article-title>. Historical review of glasses used for parenteral packaging</article-title>
    <source>71(4), 279-296</source>
    <volume>71</volume>
    <issue>4</issue>
    <fpage>279</fpage>
    <lpage>296</lpage>
    Schaut, R. A., Weeks, W. P. J. P. j. o. p. s., &amp; technology. (2017). Historical review of glasses used for parenteral packaging. 71(4), 279-296.
  </mixed-citation>
</ref>
<ref id="Shirisha">
  <label>13</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Shirisha, V., Ghosh, S., Rajni, B., Banji, D. J. R. J. o. P., &amp; Technology</person-group>
    <year>2014</year>
    <article-title>. An Updated Review on IPQC Tests for Sterile and Non Sterile Products</article-title>
    <source>7(2), 255-265</source>
    <volume>7</volume>
    <issue>2</issue>
    <fpage>255</fpage>
    <lpage>265</lpage>
    Shirisha, V., Ghosh, S., Rajni, B., Banji, D. J. R. J. o. P., &amp; Technology. (2014). An Updated Review on IPQC Tests for Sterile and Non Sterile Products. 7(2), 255-265.
  </mixed-citation>
</ref>
<ref id="United">
  <label>14</label>
  <mixed-citation publication-type="journal">
    <source>United States Pharmacopeia</source>
    <page-range>harmacopeia</page-range>
    United States Pharmacopeia 32
  </mixed-citation>
</ref>
<ref id="Williams">
  <label>15</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Williams, K</person-group>
    <year>2004</year>
    <source>Microbial contamination control in parenteral manufacturing: CRC Press</source>
    <page-range>arenteral</page-range>
    Williams, K. (2004). Microbial contamination control in parenteral manufacturing: CRC Press.
  </mixed-citation>
</ref>
</ref-list>
</back>
</article>